Active Biotech Publishes Pre-Clinical Data Regarding the TASQ Prostate Cancer Project
Posted on: Thursday, 7 September 2006, 09:21 CDT
Active Biotech (ACTI.ST) publishes a new scientific paper - "Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer" - in the next issue of the scientific journal "Prostate" (pre-available as an e-publication at NCBI National Center for Biotechnology, http://www.ncbi.nlm.nih.gov/) in collaboration with Professor John T. Isaacs of Johns Hopkins University in Baltimore, USA.
The article summarizes pre-clinical data regarding Active Biotech's project TASQ for the treatment of prostate cancer.
The data verifies TASQ's anti-angiogenic activity i.e. inhibition of the growth of new blood vessels into the tumor, and is paralleled by an inhibition of tumor growth.
The objective for the company's TASQ project is to develop a pharmaceutical product that can be administered orally for the chronic treatment of prostate cancer.
Currently TASQ is in Phase I clinical trials in prostate cancer patients.
An interim evaluation of this study will be communicated separately within short.
Phase II/III studies are scheduled to commence in 2007.
Lund, September 7, 2006 Active Biotech AB (publ)
Sven Andreasson President & CEO
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex(R) for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.
Copyright Copyright Hugin ASA 2006. All rights reserved.
SOURCE: Active Biotech
Source: MARKET WIRE
Related Articles
- Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development
- The Center for the Biology of Chronic Disease Highlights Anti-Cancer Activities of the Food Extracts Quercetin, EGCG, Glycyrrhizin, and Trans-Cinnamaldehyde
- Marshall Edwards' Phenoxodiol and Novogen's NV-128 Display Divergent Mechanisms of Action but Potent Synergistic Anti-Cancer Activity When Used in Combination
- PSI Wins Clinical Data Mart Development Services Contract From TMA DHSS
- Prominent Scientist to Lead Intrexon's Clinical Research and Development
- CVRx(R), Inc. Appoints Todd Langevin Senior Vice President of Clinical and Commercial Development
- Cleveland BioLabs President and CEO Reports Progress on Clinical and Corporate Developments
- Genaera Appoints Anthony DelConte, MD, As Vice President of Clinical Research and Development
- Genaera Appoints Michael J. Gast, MD, PhD to Lead Clinical Research and Development
- Avera Pharmaceuticals Names Joao Siffert, M.D. As Vice President, Clinical Research and Development
 |
 |
User Comments (0)
RSS Feeds